<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01003080</url>
  </required_header>
  <id_info>
    <org_study_id>09-05-145</org_study_id>
    <nct_id>NCT01003080</nct_id>
  </id_info>
  <brief_title>Unipolar vs. Bipolar Hemostasis in Total Knee Arthroplasty: A Prospective Randomized Trial</brief_title>
  <official_title>Unipolar vs. Bipolar Hemostasis in Total Knee Arthroplasty: A Prospective Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <brief_summary>
    <textblock>
      The use of Aquamantys during total knee arthroplasty will reduce drain output and the
      necessity for blood transfusions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drain Output.</measure>
    <time_frame>First 24 hours following surgery.</time_frame>
    <description>This is a measure of the average drain output collected in the first 24 hours following surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin and Hematocrit.</measure>
    <time_frame>First three days after surgery.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Knee Arthroplasty</condition>
  <arm_group>
    <arm_group_label>TKA with the Aquamantys for hemostasis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm will receive the total knee arthroplasty with the Aquamantys device used for hemostasis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TKA without the Aquamantys for hemostasis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive total knee arthroplasty using the standard treatment for hemostasis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aquamantys Device</intervention_name>
    <description>The Aquamantys is used for hemostasis in patients randomized to receive total knee arthroplasty with the device.</description>
    <arm_group_label>TKA with the Aquamantys for hemostasis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care treatment for hemostasis during a total knee arthroplasty.</intervention_name>
    <description>The active comparator arm will receive the &quot;standard-of-care&quot; for hemostasis during total knee arthroplasty. This is achieved with a unipolar Bovie electrocauterization device.</description>
    <arm_group_label>TKA without the Aquamantys for hemostasis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient indicated for total knee arthroplasty

        Exclusion Criteria:

          -  Patients undergoing revision total knee arthroplasty

          -  Patients with blood disorders

          -  Patients on chronic anti-thrombotic medication such as Coumadin

          -  Patients with a history of deep vein thrombosis

          -  Patients with a history of pulmonary embolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sun Jin Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montefiore Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jack D. Weiler Hospital-Division of Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2009</study_first_submitted>
  <study_first_submitted_qc>October 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2009</study_first_posted>
  <results_first_submitted>November 19, 2010</results_first_submitted>
  <results_first_submitted_qc>March 4, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 7, 2011</results_first_posted>
  <last_update_submitted>March 4, 2011</last_update_submitted>
  <last_update_submitted_qc>March 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Sun Jin Kim, MD (Principal Investigator)</name_title>
    <organization>Montefiore Medical Center</organization>
  </responsible_party>
  <keyword>The evaluation of hemostasis during total knee arthroplasty using the aquamantys device.</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from the medical clinics of Weiler and Montefiore hospitals under the Montefiore system in the Bronx, NY. Patients undergoing a total knee arthroplasty (TKA) were recruited over a 10 month period and either received hemostasis with the standard unipolar cauterizing device or the biplar saline system.</recruitment_details>
      <pre_assignment_details>Patients who were on anticoagulation therapy prior to their TKA were excluded from our study as this potentially would increase their amount of post-operative bleeding complicating the results of our study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TKA With the Aquamantys for Hemostasis</title>
          <description>This arm will receive the total knee arthroplasty with the Aquamantys device used for hemostasis.</description>
        </group>
        <group group_id="P2">
          <title>TKA Without the Aquamantys for Hemostasis</title>
          <description>This group will receive total knee arthroplasty using the standard treatment for hemostasis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="61"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TKA With the Aquamantys for Hemostasis</title>
          <description>This arm will receive the total knee arthroplasty with the Aquamantys device used for hemostasis.</description>
        </group>
        <group group_id="B2">
          <title>TKA Without the Aquamantys for Hemostasis</title>
          <description>This group will receive total knee arthroplasty using the standard treatment for hemostasis.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="61"/>
            <count group_id="B3" value="111"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.9" spread="10.4"/>
                    <measurement group_id="B2" value="66.3" spread="9.6"/>
                    <measurement group_id="B3" value="66" spread="9.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Drain Output.</title>
        <description>This is a measure of the average drain output collected in the first 24 hours following surgery.</description>
        <time_frame>First 24 hours following surgery.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TKA With the Aquamantys for Hemostasis</title>
            <description>This arm will receive the total knee arthroplasty with the Aquamantys device used for hemostasis.</description>
          </group>
          <group group_id="O2">
            <title>TKA Without the Aquamantys for Hemostasis</title>
            <description>This group will receive total knee arthroplasty using the standard treatment for hemostasis.</description>
          </group>
        </group_list>
        <measure>
          <title>Drain Output.</title>
          <description>This is a measure of the average drain output collected in the first 24 hours following surgery.</description>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="776" spread="334"/>
                    <measurement group_id="O2" value="778" spread="331.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin and Hematocrit.</title>
        <time_frame>First three days after surgery.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>TKA With the Aquamantys for Hemostasis</title>
          <description>This arm will receive the total knee arthroplasty with the Aquamantys device used for hemostasis.</description>
        </group>
        <group group_id="E2">
          <title>TKA Without the Aquamantys for Hemostasis</title>
          <description>This group will receive total knee arthroplasty using the standard treatment for hemostasis.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="61"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Operator dependent modifications may affect the standardization of the procedure; Surgeon is not blinded to the treatment used on each patient.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Sun Jin Kim</name_or_title>
      <organization>Montefiore Medical Center</organization>
      <phone>718-920-2060</phone>
      <email>sukim@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

